IGC Pharma, Inc.IGCNYSE
Loading
Cash Flow Under PressureContracting
Percentile Rank36
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-5.28M
↑ 12% vs avg
Percentile
P36
Within normal range
Streak
5 yr
Consecutive growthContracting
Average
$-5.98M
Historical baseline
PeriodValueYoY Change
2025$-5.28M+7.6%
2024$-5.71M+25.5%
2023$-7.67M+6.9%
2022$-8.23M+33.6%
2021$-12.39M+5.7%
2020$-13.14M-287.7%
2019$-3.39M-59.0%
2018$-2.13M-38.7%
2017$-1.54M-449.1%
2016$-279887.00-